慢性粒细胞白血病病人Mcl一1基因和Bcr／Abl基因的表达及临床意义  

The expression and clinical significance of MCL - 1 and BAR/ABL genes in chronic myeloid leukemia

作　　者：于素清[1] 苗玉[2] 

机构地区：[1]青岛大学医学院附属医院检验科,山东青岛266003 [2]青岛大学医学院附属医院黄岛分院检验科,山东青岛266003

出　　处：《医学检验与临床》2011年第5期1-3,共3页Medical Laboratory Science and Clinics

摘　　要：目的探讨慢性粒细胞白血病（CML）病人Mcl—l基因和Bcr／Abl融合基因的表达水平及临床意义。方法应用实时荧光定量PCR技术检测了4l例cML病人（包括慢性期15倒、加速期6例、急变期6例、伊马替尼治疗后遗传学完全缓解8例及非伊马替尼治疗的未缓解的CML病人6例）骨髓标本Mel—l基因、Ber／Abl融合基因的表达水平，以10例正常人作为对照。结果CML各组Mcl—I和Bcr／AblmRNA的表达水平差异均有显著性（X2=19．12—36．08，P〈0．05）。伊马替尼治疗组与正常对照组Mel—lmRNA的表达明显低于其他各组（z=2．547—3．254，P〈0．05）；加速期、急变期及非伊马替尼治疗组之间Mcl—lmRNA的表达水平差异无显著性（z=0．481一1．922，P〉0．05），但均明显高于慢性期（z=2．65—3．465，P〈0．05）。Ber／AblmRNA在慢性期、加速期、急变期及非伊马替尼治疗组之间表达差异无显著性（z=0．48—1．196，P〉0．05）。CML患者Mel—l与Bcr／AblmRNA的表达水平呈正相关（r=0．68，P〈0．05）。结论Mcl—l和Ber／Abl与CML的病情密切相关，参与cML的发生和发展，是判断病情进展及预后的分子标记物。Objective To investigate the expression of MCL- 1 and Bcr/Abl genes in patients with chronic myeloid leukemia（CML） and explore their clinical significance. Methods The expressions of Mcl - 1 and Bcr/Abl genes were analyzed in 41 patients with CML in different phases （ 15 patients of chronic phase, 6 patients of accelerated phase, 6 patients of blastic phase, 8 patients of complete cytogenetic remission patients treated with imatinib and 6 patients of non - imatinib treated patients） using SYBR Green I real - time quantitative reverse transcription polymerase chain reaction （real - time PCR）. Ten healthy subjects were used as normal controls. Results Both Mcl - 1 and Bcr/Abl mRNA expressions were significantly high among CML patients（x2 = 19.12 -36.08, p 〈 0.05）, whereas the expression level of Mcl - 1 gene was significantly lower in patients treated with imatinib and the normal controls than the other ones（z = 2.647 - 3.254, p 〈 0.05）. The expressions of Mcl - 1 mRNA in AP, BP and non - imatinib treated group showed no differences （z = 0.481 - 1.922, p 〉 0.05）, but higher than that of CP group （z = 2.65 - 3.465, p 〈 0.05 ）. For Bcr/Abl mRNA, there were no differences between CP, AP, BP and no - imatinib treated group （z=0.48 - 1.196, p 〉 0.05 ）. Moreover, the expression of Mcl - 1 gene was positively correlated with that of Bcr/Abl gene （r = O. 68,p 〈 0.05）. Conclusion The overexpression of Mcl- 1 and Bcr/Abl genes play an important role in the occurrence and development of CML. Mcl - 1 gene could represent both a valuable biomarker and attractive candidate for monitoring the advancement and prognosis of CML.

关 键 词：白血病 髓样 慢性 Nel一1基因 融合基因Bcr/Abl 实时荧光RT—PCR 伊马替尼 

分 类 号：R733.72[医药卫生—肿瘤]